Nexavar
(Sorafenib)ApprovedSmall molecule
BayerSorafenib is used to treat certain types of cancer, including liver cancer, kidney cancer, and thyroid cancer. It works by slowing or stopping the growth of cancer cells in the body.[2] Nexavar is currently approved and in use across 44 indications[4].[1]
Nexavar is one of 749 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Approved.
44
Indications
622
Total Trials
8
Active Trials
748
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 44 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Nexavar
BayerApproved
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Tianeptine
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hepatocellular Carcinoma37 trials
Show 34 more trials
Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.
Completed·—·N/A·NCT06030895·100 enrolled
Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma
Unknown status·—·Phase 4·NCT02504983·200 enrolled
Renal Cell Carcinoma14 trials
Show 11 more trials
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases
Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT01444807·132 enrolled
Sorafenib9 trials
Show 6 more trials
Sorafenib PK in Patients With Advanced HCC and Child-Pugh B
Terminated·—·Phase 2·NCT04051853·5 enrolled
Kidney Cancer6 trials
Thyroid Cancer6 trials
Show 3 more trials
88 more indications
Non-Small Cell Lung Cancer6 trials
Breast Cancer6 trials
Liver Cancer5 trials
Show 2 more trials
Pancreatic Cancer4 trials
Show 1 more trial
Leukemia4 trials
Melanoma3 trials
Hepatocellular Cancer3 trials
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT03037437·64 enrolled
Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients
Completed·—·Phase 1·NCT00997022·14 enrolled
Bevacizumab3 trials
Myelodysplastic Syndrome3 trials
Sorafenib in Myelodysplastic Syndrome
Terminated·—·Phase 2·NCT00510289·19 enrolled
Acute Myeloid Leukemia3 trials
Glioblastoma2 trials
Metastatic Melanoma2 trials
Thyroid Carcinoma2 trials
Prospective2 trials
Refractory Solid Tumors2 trials
Biliary Tract Cancer2 trials
Soft Tissue Sarcoma2 trials
Patients With Solid Tumors2 trials
Acute Leukemia2 trials
Recurrent Sarcoma1 trial
Glioma1 trial
Metastatic Renal Cell Cancer1 trial
Function1 trial
Cardiovascular1 trial
COVID-191 trial
Non-Small Cell Lung Carcinoma1 trial
Maximum Tolerated Dose1 trial
Renal Cell Cancer1 trial
Refractory Cancer1 trial
Astrocytoma1 trial
Primary Peritoneal Cancer1 trial
Head and Neck Squamous Cell Cancer1 trial
Keloid1 trial
Sorafenib for Patients With Extensive Keloids
Terminated·—·Phase 2·NCT01425216·60 enrolled
Capecitabine1 trial
Acute Monocytic Leukemia1 trial
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2/3·NCT05313958·43 enrolled
Small Cell Lung Cancer1 trial
Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Terminated·—·Phase 2·NCT00726986·18 enrolled
Cholangiocarcinoma1 trial
Second-line Therapy1 trial
Colorectal Cancer1 trial
Acute Lymphoblastic Leukemia1 trial
Ovarian Cancer1 trial
Squamous Cell Carcinoma1 trial
Pulmonary Arterial Hypertension1 trial
Postoperative Adjuvant Treatment1 trial
Patients With Advanced Solid Tumors1 trial
Glioblastoma Multiforme1 trial
Randomized1 trial
Gallbladder Carcinoma1 trial
Pancreatic Carcinoma1 trial
Trial1 trial
Transitional Cell Carcinoma1 trial
Induction Therapy1 trial
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
Recruiting·—·Phase 2·NCT06221683·500 enrolled
Pediatric Patients1 trial
Metastasis1 trial
Adenovirus1 trial
Collecting Duct Carcinoma1 trial
Stem Cell Transplant1 trial
Gastrointestinal Tumors1 trial
Adjuvant Therapy1 trial
Maintenance Therapy1 trial
Induction Chemotherapy1 trial
Advanced Stage1 trial
Lymphoma1 trial
Peritoneal Cancer1 trial
Metastatic Colorectal Cancer1 trial
Uveal Melanoma1 trial
Metastatic Head and Neck Cancer1 trial
Rhabdomyosarcoma1 trial
Regulatory
FDA Approval Timeline[5]
Dec 20, 2005
NEXAVAR
NDA NDA021923
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Nexavar drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Sorafenib. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Serine/threonine-Protein Kinase RAF Inhibitor; Platelet-Derived Growth Factor Receptor Beta Inhibitor; Serine/threonine-Protein Kinase B-RAF Inhibitor; Stem Cell Growth Factor Receptor Inhibitor; Tyrosine-Protein Kinase Receptor FLT3 Inhibitor; Tyrosine-Protein Kinase Receptor RET Inhibitor; Vascular Endothelial Growth Factor Receptor Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company